General Description
Dapagliflozin (INN,[2] USAN,[3] trade name Farxiga far-SEE-g? in the U.S. and Forxiga in the EU and Russia) is a drug of the gliflozin class, used to treat type 2 diabetes. It was developed by Bristol-Myers Squibb in partnership with AstraZeneca.